These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

529 related articles for article (PubMed ID: 29058822)

  • 21. Atopy and Response to Omalizumab Treatment in Chronic Spontaneous Urticaria.
    Costa C; Esteves Caldeira L; Paulino M; Santos DF; Silva SL
    Int Arch Allergy Immunol; 2024; 185(3):260-266. PubMed ID: 38113870
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The impact of omalizumab on quality of life and its predictors in patients with chronic spontaneous urticaria: Real-life data.
    Salman A; Demir G; Bekiroglu N
    Dermatol Ther; 2019 Jul; 32(4):e12975. PubMed ID: 31145524
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Omalizumab vs. placebo in the management of chronic idiopathic urticaria: a systematic review.
    Carrillo DC; Borges MS; García E; Egea E; Serrano CD
    World Allergy Organ J; 2014; 7(1):72. PubMed ID: 25566332
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Evaluation of a Guidelines-Based Approach to the Treatment of Chronic Spontaneous Urticaria.
    Sánchez J; Zakzuk J; Cardona R
    J Allergy Clin Immunol Pract; 2018; 6(1):177-182.e1. PubMed ID: 28709817
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A Specialized Therapeutic Approach to Chronic Urticaria Refractory to H1-Antihistamines Improves Disease Burden: The Spanish AWARE Experience.
    Gimenez-Arnau A; Bartra J; Ferrer M; Jauregui I; Borbujo J; Figueras I; Muñoz-Bellido FJ; Pedraz J; Serra-Baldrich E; Tejedor-Alonso MA; Velasco M; Terradas P; Labrador M
    J Investig Allergol Clin Immunol; 2022 Jun; 32(3):191-199. PubMed ID: 33349612
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Chronic urticaria in the real-life clinical practice setting in the UK: results from the noninterventional multicentre AWARE study.
    Savic S; Leeman L; El-Shanawany T; Ellis R; Gach JE; Marinho S; Wahie S; Sargur R; Bewley AP; Nakonechna A; Randall R; Fragkas N; Somenzi O; Marsland A
    Clin Exp Dermatol; 2020 Dec; 45(8):1003-1010. PubMed ID: 32246853
    [TBL] [Abstract][Full Text] [Related]  

  • 27. What are the effects of omalizumab in refractory chronic spontaneous urticaria?
    López M; Navajas-Galimany L
    Medwave; 2015 Dec; 15 Suppl 3():e6346. PubMed ID: 26731420
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Patients With Chronic Spontaneous Urticaria Who Have Wheals, Angioedema, or Both, Differ Demographically, Clinically, and in Response to Treatment-Results From CURE.
    Buttgereit T; Vera C; Aulenbacher F; Church MK; Hawro T; Asero R; Bauer A; Bizjak M; Bouillet L; Dissemond J; Fomina D; Giménez-Arnau AM; Grattan C; Gregoriou S; Kulthanan K; Kasperska-Zajac A; Kocatürk E; Makris M; Kolkhir P; Weller K; Magerl M; Maurer M
    J Allergy Clin Immunol Pract; 2023 Nov; 11(11):3515-3525.e4. PubMed ID: 37604426
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Long-term management of chronic spontaneous urticaria with omalizumab.
    Pinto Gouveia M; Gameiro A; Pinho A; Gonçalo M
    Clin Exp Dermatol; 2017 Oct; 42(7):735-742. PubMed ID: 28649751
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Treatment of chronic spontaneous urticaria with an inadequate response to H1-antihistamines: an expert opinion.
    Vestergaard C; Toubi E; Maurer M; Triggiani M; Ballmer-Weber B; Marsland A; Ferrer M; Knulst A; Giménez-Arnau A
    Eur J Dermatol; 2017 Feb; 27(1):10-19. PubMed ID: 27882879
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Omalizumab for the treatment of chronic idiopathic or spontaneous urticaria.
    Maurer M; Rosén K; Hsieh HJ; Saini S; Grattan C; Gimenéz-Arnau A; Agarwal S; Doyle R; Canvin J; Kaplan A; Casale T
    N Engl J Med; 2013 Mar; 368(10):924-35. PubMed ID: 23432142
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clinical efficacy of omalizumab in chronic spontaneous urticaria is associated with a reduction of FcεRI-positive cells in the skin.
    Metz M; Staubach P; Bauer A; Brehler R; Gericke J; Kangas M; Ashton-Chess J; Jarvis P; Georgiou P; Canvin J; Hillenbrand R; Erpenbeck VJ; Maurer M
    Theranostics; 2017; 7(5):1266-1276. PubMed ID: 28435464
    [No Abstract]   [Full Text] [Related]  

  • 33. Angioedema is an unfavorable factor for the response to omalizumab in chronic spontaneous urticaria: A retrospective study.
    Serarslan G; Uzun M; Doğramacı AÇ; Çelik E
    Dermatol Ther; 2019 Jan; 32(1):e12752. PubMed ID: 30238582
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Omalizumab for the treatment of chronic spontaneous urticaria: A meta-analysis of randomized clinical trials.
    Zhao ZT; Ji CM; Yu WJ; Meng L; Hawro T; Wei JF; Maurer M
    J Allergy Clin Immunol; 2016 Jun; 137(6):1742-1750.e4. PubMed ID: 27040372
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A randomized, placebo-controlled, dose-ranging study of single-dose omalizumab in patients with H1-antihistamine-refractory chronic idiopathic urticaria.
    Saini S; Rosen KE; Hsieh HJ; Wong DA; Conner E; Kaplan A; Spector S; Maurer M
    J Allergy Clin Immunol; 2011 Sep; 128(3):567-73.e1. PubMed ID: 21762974
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effective treatment of different phenotypes of chronic urticaria with omalizumab: Case reports and review of literature.
    Kasperska-Zajac A; Jarząb J; Żerdzińska A; Bąk K; Grzanka A
    Int J Immunopathol Pharmacol; 2016 Jun; 29(2):320-8. PubMed ID: 26729404
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Efficacy and safety of omalizumab in Chinese patients with anti-histamine refractory chronic spontaneous urticaria.
    Yuan W; Hu S; Li M; Yang L; Liu L; Zheng M; Guo Z; Song Z; Zhang C; Diao Q; Xu J; Richard A; Patwardhan M; Lyu T; Uddin A; Fogel R; Ligueros-Saylan M; Zheng J
    Dermatol Ther; 2022 Apr; 35(4):e15303. PubMed ID: 34984792
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Improvement of patient outcomes following therapeutic optimization of chronic urticaria: two-year data from France as part of the international real-life AWARE study.
    Giordano-Labadie F; Becherel PA; Pralong P; Outtas O; Ruer-Mulard M; Berard F; Greco M; Lacour JP; Debons-Peyroutet M; Pelvet B; Lamirand A; Guillet G
    Eur J Dermatol; 2021 Apr; 31(2):217-224. PubMed ID: 34001470
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Omalizumab for treatment of idiopathic angioedema.
    Goswamy VP; Lee KE; McKernan EM; Fichtinger PS; Mathur SK; Viswanathan RK
    Ann Allergy Asthma Immunol; 2022 Nov; 129(5):605-611.e1. PubMed ID: 35914662
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Clinical characteristics and management of chronic spontaneous urticaria in patients refractory to H
    Chu CY; Al Hammadi A; Agmon-Levin N; Atakan N; Farag A; Arnaout RK; Kannenberg S; Kulthanan K; Mubarak A; Zaitoun F; Crowe S; Malfait S; Cooke K; Dekker EL
    World Allergy Organ J; 2020 Apr; 13(4):100117. PubMed ID: 32382379
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 27.